Author

David Barros-Aguirre

GlaxoSmithKline (Spain)ORCID 0000-0002-4099-0438Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 1

Frequent Co-Authors

Alfonso Mendoza-LosanaiD· 2 shared Joaquín Rullás· 2 shared Rubén González del Río· 2 shared Adolfo García-Pérez· 1 shared Ángel Santos-Villarejo· 1 shared Charles J. ThompsoniD· 1 shared Eric L. NuermbergeriD· 1 shared Esther Pérez‐HerrániD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Alfonso Mendoza-LosanaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Sanfetrinem, an oral beta-lactam antibiotic repurposed for the treatment of tuberculosis

Santiago Ramón‐García, Rubén González del Río, María Pilar Arenaz-Callao, Helena I. Boshoff, Joaquín Rullás, Sara Anca, Mónica Cacho, Esther Porras de Francisco, Esther Pérez‐Herrán, Ángel Santos-Villarejo, Alfonso Mendoza-Losana, Santiago B. Ferrer, Charles J. Thompson, David Barros-Aguirre, Robert H. Bates

This paper identifies sanfetrinem cilexetil as a promising oral beta-lactam antibiotic for tuberculosis treatment through preclinical studies showing its activity against Mtb and potential for repurposing.

Drug Resistance Updates · Feb 15, 2025Peer-reviewedMicrobiology

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosis

Lourdes Encinas, Si‐Yang Li, Joaquín Rullás, Rokeya Tasneen, Sandeep K. Tyagi, Heena Soni, Adolfo García-Pérez, Jin Lee, Rubén González del Río, Jaime de Mercado, Verónica Sousa, Izidor Sosič, Stanislav Gobec, Alfonso Mendoza-Losana, Paul J. Converse, , Eric L. Nuermberger

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.

Antimicrobial Agents and Chemotherapy · Sep 30, 2024Peer-reviewedPharmacology & Toxicology